Bringing Adaptive Therapies to the Clinic Senti Biosciences, is a synthetic biology startup developing new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
Senti Biosciences, Inc.
Senti Biosciences, is a synthetic biology startup developing new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/senti-biosciences” connections=”true” suffix=””]
Senti scientific co-founder Wilson Wong created a split, universal, and programmable (SUPRA) CAR system. Instead of relying on a single fixed CAR, the technology splits the molecule into a two-component receptor system. It comprises universal receptors, dubbed zipCARs, expressed on the T cells, plus adaptor molecules, called zipFv molecules, which carry an antibody that targets a specific antigen on the tumor cell. Both components use leucine zippers to bind to each other, allowing the engineered T cells to seek and destroy cancer. This revised CAR-T is designed to target two markers for the disease, vastly improving its chance of extending the use of these drugs into hard-to-hit solid tumors while improving the specificity of the drug to cancer tissue.
In Feb 2018, Senti Biosciences raised $53 Mn in Series A funding led by New Enterprise Associates, with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital.